Literature DB >> 17766701

An integrated model for glucose and insulin regulation in healthy volunteers and type 2 diabetic patients following intravenous glucose provocations.

Hanna E Silber1, Petra M Jauslin, Nicolas Frey, Ronald Gieschke, Ulrika S H Simonsson, Mats O Karlsson.   

Abstract

An integrated model for the regulation of glucose and insulin concentrations following intravenous glucose provocations in healthy volunteers and type 2 diabetic patients was developed. Data from 72 individuals were included. Total glucose, labeled glucose, and insulin concentrations were determined. Simultaneous analysis of all data by nonlinear mixed effect modeling was performed in NONMEM. Integrated models for glucose, labeled glucose, and insulin were developed. Control mechanisms for regulation of glucose production, insulin secretion, and glucose uptake were incorporated. Physiologically relevant differences between healthy volunteers and patients were identified in the regulation of glucose production, elimination rate of glucose, and secretion of insulin. The model was able to describe the insulin and glucose profiles well and also showed a good ability to simulate data. The features of the present model are likely to be of interest for analysis of data collected in antidiabetic drug development and for optimization of study design.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17766701     DOI: 10.1177/0091270007304457

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  36 in total

1.  Transforming parts of a differential equations system to difference equations as a method for run-time savings in NONMEM.

Authors:  K J F Petersson; L E Friberg; M O Karlsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2010-09-29       Impact factor: 2.745

Review 2.  A Comprehensive Review of Novel Drug-Disease Models in Diabetes Drug Development.

Authors:  Puneet Gaitonde; Parag Garhyan; Catharina Link; Jenny Y Chien; Mirjam N Trame; Stephan Schmidt
Journal:  Clin Pharmacokinet       Date:  2016-07       Impact factor: 6.447

3.  Optimization of the intravenous glucose tolerance test in T2DM patients using optimal experimental design.

Authors:  Hanna E Silber; Joakim Nyberg; Andrew C Hooker; Mats O Karlsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2009-06-25       Impact factor: 2.745

4.  Approaches to handling pharmacodynamic baseline responses.

Authors:  Chantaratsamon Dansirikul; Hanna E Silber; Mats O Karlsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2008-04-30       Impact factor: 2.745

5.  Exploring inductive linearization for pharmacokinetic-pharmacodynamic systems of nonlinear ordinary differential equations.

Authors:  Chihiro Hasegawa; Stephen B Duffull
Journal:  J Pharmacokinet Pharmacodyn       Date:  2017-05-26       Impact factor: 2.745

6.  Model-Based Residual Post-Processing for Residual Model Identification.

Authors:  Moustafa M A Ibrahim; Rikard Nordgren; Maria C Kjellsson; Mats O Karlsson
Journal:  AAPS J       Date:  2018-07-02       Impact factor: 4.009

7.  Exact Gradients Improve Parameter Estimation in Nonlinear Mixed Effects Models with Stochastic Dynamics.

Authors:  Helga Kristin Olafsdottir; Jacob Leander; Joachim Almquist; Mats Jirstrand
Journal:  AAPS J       Date:  2018-08-01       Impact factor: 4.009

8.  Assessment of glycemic response to an oral glucokinase activator in a proof of concept study: application of a semi-mechanistic, integrated glucose-insulin-glucagon model.

Authors:  Karen B Schneck; Xin Zhang; Robert Bauer; Mats O Karlsson; Vikram P Sinha
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-12-22       Impact factor: 2.745

Review 9.  Pharmacokinetic/pharmacodynamic modelling in diabetes mellitus.

Authors:  Cornelia B Landersdorfer; William J Jusko
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

10.  Application of the integrated glucose-insulin model for cross-study characterization of T2DM patients on metformin background treatment.

Authors:  Joanna Parkinson; Bengt Hamrén; Maria C Kjellsson; Stanko Skrtic
Journal:  Br J Clin Pharmacol       Date:  2016-08-16       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.